A PHASE II, MULTI-CENTER, OPEN LABEL STUDY OF MELPHALAN, PREDNISONE, THALIDOMIDE AND DEFIBROTIDE IN ADVANCED AND REFRACTORY MULTIPLE MYELOMA PATIENTS

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-003293-25-IT

Enrollment

Registered

2005-10-26

Start date

2005-10-05

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MULTIPLE MYELOMA MedDRA version: 6.1 Level: PT Classification code 10051381

Interventions

Trade Name: DELTACORTENE FTE*10 CPR 25MG Pharmaceutical Form: Tablet INN or Proposed INN: Prednisone CAS Number: 53-03-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration num

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026